Characterising novel pathways to schizophrenia

Medical Journal of Australia

Volumn 190, Issue 4 SUPPL., 2009, Pages

  Hickie, Ian B ^a   McGorry, Patrick D ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; ESTROGEN; LITHIUM; OMEGA 3 FATTY ACID;

ADOLESCENT DEVELOPMENT; ARTICLE; BRAIN DEVELOPMENT; EARLY INTERVENTION; FRONTAL LOBE; HUMAN; NEUROPROTECTION; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA;

EID: 61849105882     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02365.x     Document Type: Article

References (27)

1. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
2. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006; 7: 818-827.
3. Hickie IB, Groom GL, McGorry PD, et al. Australian mental health reform: time for real outcomes. Med J Aust 2005; 182: 401-406.
4. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
5. McGrath J. Dissecting the heterogeneity of schizophrenia outcomes. Schizophr Bull 2008; 34: 247-248.
6. van Os J, Krabbendam L, Myin-Germeys I, Delespaul P. The schizophrenia envirome. Curr Opin Psychiatry 2005; 18: 141-145.
7. Caspi A, Moffitt TE. Gene - environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006; 7: 583-590.
8. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-328.
9. McGrath JJ, Susser ES. New directions in the epidemiology of schizophrenia. Med J Aust 2009; 190 (4 Suppl): S7-S9.
10. Hermens DF, Lubman DI, Ward PB, et al. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 2009; 190 (4 Suppl): S22-S25.
11. Hickie IB, Banati R, Stewart CH, Lloyd AR. Are common childhood or adolescent infections risk factors for schizophrenia and other psychotic disorders? Med J Aust 2009; 190 (4 Suppl): S17-S21.
12. Kulkami J. Cestrogen - a new treatment approach for schizophrenia? Med J Aust 2009; 190 (4 Suppl): S37-S38.
13. McGorry PD, Yung AR, Pantelis C, Hickie IB. A clinical trials agenda for testing interventions in earlier stages of psychotic disorders. Med J Aust 2009; 190 (4 Suppl): S33-S36.
14. Wood SJ, Pantelis C, Yung AR, et al. Brain changes during the onset of schizophrenia: implications for neurodevelopmental theories. Med J Aust 2009; 190 (4 Suppl): S10-S13.
15. Brewer WJ, Francey SM, Wood SJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 2005; 162: 71-78.
16. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-928.
17. McGorry PD. Recommended haloperidol and risperidone doses in first-episode psychosis. J Clin Psychiatry 1999; 60: 794-795.
18. Lambert M, Conus P, Schimmelmann BG, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005; 38: 206-213.
19. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361-370.
20. Berger GE, Proffitt TM, McConchie M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1867-1875.
21. Berger GE, Wood S, McGorry PD. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol Bull 2003; 37: 79-101.
22. Bennett MR. Synapse formation and regression in the cortex during adolescence and in schizophrenia. Med J Aust 2009; 190 (4 Suppl): S14-S16.
23. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616-622.
24. Banati R, Hickie IB. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med J Aust 2009; 190 (4 Suppl): S26-S32.
25. McGorry PD, Tanti C, Stokes R, et al. headspace: Australia's National Youth Mental Health Foundation - where young minds come first. Med J Aust 2007; 187 (7 Suppl): S68-S70.
26. Crosbie DW. Mental health policy - stumbling in the dark? Med J Aust 2009; 190 (4 Suppl): S43-S45.
27. Lambert TJR, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190 (4 Suppl): S39-S42.